Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806058) titled 'An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Condition: Pancreatic Cancer

Intervention: Drug: HRS-7172 + AG + SHR-1316 Drug: HRS-7172 + AG + SHR-1316 Drug: HRS-7172 + AG Drug: HRS-7172 + AG + SHR-1316 Drug: HRS-717 + HRS-4642+SHR-1316 Drug: HRS-717 + HRS-4642+SHR-1316 Drug: HRS-717 + HRS-4642

R...